StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer All Other Oncology — Worldwide revenues by Year

All Other Oncology — Worldwide revenues ($M) ($M)

Pfizer All Other Oncology — Worldwide revenues: $1,127M in FY2025, up 0.4% from a year earlier.

Latest, FY2025
1,127
Period ended Dec 31, 2025
Change on a year earlier
+0.4%
1,122 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| All other Oncology | 1,127 | 1,122 | — | 1% | 635 | 603 | 5% | 492 | 519 | (5%) | (5%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up all Other Oncology — Worldwide revenues

Cite this data

StockData. (2026). Pfizer All Other Oncology — Worldwide revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/other-onc-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.